

November 1, 2022

**MacTel Phase 3
Clinical Trial Participants
Protocols NTMT-03A and NTMT-03B**

Re: Clinical Trial Participant – Thank You Letter

Dear Patient,

On behalf of Neurotech Pharmaceuticals and your clinical research site investigators, we want to sincerely thank you for your completed participation in either the NTMT-03A or NTMT-03B clinical trial protocol. Your commitment and the commitment of all other participants allowed us to meet our primary study objectives for both protocols.

Together, 228 treated trial participants collectively completed more than 2,050 visits to 47 sites across 5 countries (Australia, France, Germany, United Kingdom, and the United States of America) in the MacTel Phase 3 program. In late September 2022, we locked both study databases as all participants had completed their final study visits. Last month, we received the overall topline results for both trials. In response, Neurotech is planning a formal press release tomorrow to share this information with the public and medical community.

If you are interested in learning which treatment you received (NT-501 or sham), you may now ask your treating physician to disclose this information to you.

We know that you will likely have many additional questions and request that you please direct those to your treating physician and clinical research site staff. It may take time for us to answer all your questions, but we are committed to sharing what we know as soon as permissible.

Right now, we are continuing to fully evaluate all study results for both protocols and are starting to draft our final clinical study reports. We will be working through the regulatory process with the FDA and appropriate agencies.

When we talk about trial results, we tend to think in terms of numbers, trends and figures. Neurotech Pharmaceuticals understand that behind each of those numbers is a person who agreed to take part in our trials. It is thanks to each of you and your treating physicians, that patients suffering with Type 2 Macular Telangiectasia now have hope. Thanks again to you all!

Sincerely,

Thomas M. Aaberg, Jr. M.D.
Chief Medical Officer
Neurotech Pharmaceuticals, Inc.